Linike Medical Group EBITDA per Share
EBITDA per Share of Linike Medical Group (LNMG) as of Oct 31, 2026.
Get this data via API
Financial Data API
EBITDA per Share
0.00USD
YoY
-1,360.47%
Last updated:
EBITDA per Share of Linike Medical Group is 2025 0.00 USD. EBITDA per Share of Linike Medical Group was 2024 -0.00 USD. It decreases by -1,360.47% higher compared to the previous year.
The Linike Medical Group EBITDA per Share history
3 Years
10 Years
25 Years
Max
EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
-0.00 USD
Jan 1, 2025
0.00 USD
| YEAR | EBITDA per Share | YoY |
|---|---|---|
| 0.00USD | -1,360.47% | |
| -0.00USD | -124.71% | |
| 0.00USD | -1,534.67% | |
| -0.00USD | +76.19% | |
| -0.00USD | -55.73% | |
| -0.00USD | +8,100.93% | |
| -0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Linike Medical Group Stock analysis
What does Linike Medical Group do? Linike Medical Group Ltd, headquartered in Las Vegas, Nevada, operates in the energy sector, focusing on oil and natural gas exploration. The company, listed on 17 May 2012, has subsidiaries including China Linike Medical Group Ltd and Sichuan Huarong Zhengtai Medical Technology Co., Ltd. Its primary business involves the exploration and development of energy resources. Linike Medical Group is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Linike Medical Group stock
On Eulerpool you can find the complete historical development of EBITDA per Share Linike Medical Group since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Linike Medical Group
All Key Metrics — Linike Medical Group
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth